logo
World First: Scientists Printed Penises For Pigs And Restored Their Erections

World First: Scientists Printed Penises For Pigs And Restored Their Erections

Yahoo07-03-2025

A 3D-printed penis implant has restored erectile function to rabbits and pigs in a world first.
Pigs with damage to their penile tissue that received the one-of-a-kind surgery not only achieved erections, their rates of successfully producing offspring increased from 25 percent to 100 percent.
The penis has one of the most complex vascular network structures in the human body. For years now, researchers have been working on a model of the corpus cavernosum, the spongy tissue of the penile shaft, that could help those with erectile defects.
The recent study by a team from China, the US, and Japan presents a new physiological model that can reproduce erections in large, living animals.
To create the model, researchers mimicked the corpus cavernosum through the creation of a hydrogel-based scaffolding – one that is strong enough to withstand the internal pressure when the structure fills with blood.
The team then seeded the scaffolding with pig or rabbit endothelial cells, which are the main cells that line blood vessels. Endothelial cells (ECs) can create an "adaptable life-support system" in vessel-rich tissues, helping restore and improve function.
To test this idea out in the corpus cavernosum of Bama pigs and New Zealand rabbits, researchers implanted the hydrogel and ECs into dozens of animals with erectile defects.
Some rabbits and pigs received the artificial penis implant without ECs, but those that received the ECs and the implant showed better erectile function overall. In fact, their outcomes approached that of an animal without erectile dysfunction.
"These findings indicate that the implants markedly improved functional recovery, and the combination with ECs further enhanced this effect, demonstrating notable improvements in tissue regeneration and functional recovery," write the authors, led by biological engineer Zhenxing Wang from South China University of Technology.
"The fertility of the EC groups demonstrates the recovery of erectile function and the ability to ejaculate, suggesting the restoration of the cavernous tissue in the treated males."
Pigs that received the EC model, for instance, showed low inflammation levels after surgery, and as the hydrogel scaffolding degraded at the defect site, new tissue progressively formed.
When the pigs were allowed to breed a few weeks after surgery, pregnancy rates rose from just 25 percent in the defect group to 75 percent in the implant without ECs group.
Male pigs that received the implant with ECs successfully impregnated every single female pig they mated with.
The new penis model may prove useful in the future treatment of human erectile dysfunction and diseases that scar the deeper tissues of the penis, causing painful erections.
It could also help inform the development of other artificial, vessel-rich organs, like the heart.
"Currently, developing transplant materials that support nerve regeneration and effectively integrate with the host's urethra and vascular networks presents a major challenge," the authors write.
"These approaches could help overcome current obstacles in repairing large-scale penile injuries."
Some studies suggest that more than half of men aged 40 to 70 experience mild to moderate erectile dysfunction that increases with age, and while the condition is treatable, it is not always curable.
"These findings underscore the potential clinical applications of biomimetic corpus cavernosum for the treatment of penile injuries," conclude Wang and colleagues.
"Furthermore, this study advances the clinical application of 3D-printed artificial tissue organs."
The study was published in Nature Biomedical Engineering.
Chewing Wood Could Give Your Brain an Unexpected Boost
Tinnitus Seems to Be Somehow Connected to a Crucial Bodily Function
Misdiagnosis of Chronic Conditions as 'In Your Head' Causes Lasting Damage

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Business Wire

time3 days ago

  • Business Wire

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. 'This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,' said Perry Sternberg, Chief Executive Officer of Sydnexis. 'This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.' The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. 'The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,' said Patrick Johnson, Ph.D., President of Sydnexis. 'This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.' Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. 'As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,' said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. 'The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.' About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.

EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma
EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma

Yahoo

time4 days ago

  • Yahoo

EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the chemotherapy regimen for adults with newly diagnosed Stage IIb Hodgkin's lymphoma (HL) with risk factors/III/IV. The chemotherapy regimen comprises etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD). This decision follows the Committee for Medicinal Products for Human Use's (CHMP) positive opinion in April 2025. The EC's approval is based on the Phase III HD21 trial outcomes, which showed that the Adcetris-based regimen, referred to as BrECADD, met its co-primary efficacy and safety endpoints. BrECADD demonstrated superior safety as evaluated by treatment-related morbidity (TRMB) and non-inferior progression-free survival compared to the escalated doses of standard of care treatment, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP) in Europe. The HD21 study, conducted by the German Hodgkin Study Group (GHSG), was an open-label, multi-country, randomised trial assessing BrECADD's efficacy, feasibility, safety and tolerability. Adcetris, which leverages Pfizer's technology, has been previously approved in the European Union (EU) for six different indications in adults. Pfizer, along with Takeda, equally funds the co-development expenses for the ADC, except in Japan, where the latter manages the costs independently. Adcetris has received US Food and Drug Administration (FDA) approval for eight indications and was initially granted conditional marketing authorisation by the EC in October 2012. The conditions of this authorisation were fulfilled by May 2022. Takeda global oncology business unit president Teresa Bitetti stated: 'Today's approval represents a significant advancement for patients with Hodgkin lymphoma in the EU. "This approval reinforces the role of Adcetris as a backbone in the treatment of specific lymphomas, offering healthcare professionals greater flexibility to tailor treatment plans according to individual patient needs. We're proud to contribute another impactful option for those diagnosed with this challenging disease.' "EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Introduction to the In-Vitro Diagnostic Regulation (IVDR): Online Training Course with Practical Workshops (July 16-17, 2025) Led by Stuart Angell (Director, IVDeology Ltd.)
Introduction to the In-Vitro Diagnostic Regulation (IVDR): Online Training Course with Practical Workshops (July 16-17, 2025) Led by Stuart Angell (Director, IVDeology Ltd.)

Yahoo

time4 days ago

  • Yahoo

Introduction to the In-Vitro Diagnostic Regulation (IVDR): Online Training Course with Practical Workshops (July 16-17, 2025) Led by Stuart Angell (Director, IVDeology Ltd.)

Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course" has been added to offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) rules which, for the first time, takes patient impact into consideration. This will have a significant impact on all manufacturers of IVDs as about 80 per cent of all devices will now require some form of conformity assessment by a Notified Body. This seminar will clarify the requirements applicable to in-vitro diagnostic devices under the new regulation, highlight the major changes to responsibility and product data expectations and provide a thorough understanding of the impact on the industry. Practical workshops over the two days will help consolidate the information provided. Certifications CPD: 12 hours for your records Certificate of completion Who Should Attend? Regulatory affairs personnel Persons responsible for regulatory compliance Quality assurance professionals Those responsible for OEM/subcontractor control of IVDs Economic operators, importers, distributors Agenda Day 1 Introduction to IVDs Definition of an IVD Why are IVDs regulated separately? Investigating standards and their use Exploring CE marking Historical overview of the current IVD Directive (98/79/EC) Examining the structure and content of the IVD Directive Introduction to IVD Regulation (EU) 2017/746 How did we come from the Directive to the Regulation? Main drivers for change Scale of change Structure and Annex Notified Bodies How has the role of the Notified Bodies changed under the IVD Regulation? Conformity assessment IVD Regulation - key changes Persons responsible for regulatory compliance Economic operators, importers, distributors UDI Software Intended use/intended purpose (including an interactive workshop) Performance evaluation Clinical evidence Compiling the technical documentation for an IVD Structure and content of STED Technical file vs design dossier Labelling requirements and strategies Understanding electronic instructions for use (e-IFUs) Use of language and symbols Translation requirements Traceability and EUDAMED UDIs Day 2 ISO 13485:2016 Introduction to ISO 13485 Key changes from 2012 to 2016 Where does it fit with IVDD & IVDR? Risk-based classification How are IVDs classified? Workshop: Product classification Discussion on the classification of example IVDs Risk management Regulatory requirements ISO14971 Usability Workshop: Risk management Clinical evidence and common specifications Scientific validity vs performance evaluation Vigilance and PMS Regulatory requirements Incident reporting/FSCA management Case studies: Reporting/recalls PMS Key timelines and practical considerations Discussion: Preparing a roadmap for transition SpeakerStuart Angell Director, IVDeology Angell, This MDTI expert is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016. He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store